Hims & Hers to offer generic semaglutide in Canada starting in 2026

Hims & Hers (NYSE:HIMS) announced plans to introduce generic semaglutide in Canada starting January 2026, making it the first country globally to offer these more affordable alternatives following the expiration of Novo Nordisk's patent and data exclusivity protections. Leveraging its digital health platform for consultations and personalized care, Hims & Hers aims to significantly expand access to weight management treatment for Canadians, where branded versions currently cost over C$200 monthly. This strategic expansion into the Canadian market is part of the company's broader international growth initiatives, with HIMS shares seeing a modest gain following the announcement, having already more than doubled in 2025.

Analysis

Hims & Hers (NYSE:HIMS) is strategically positioning itself to capitalize on the first global availability of generic semaglutide with its planned expansion into Canada in January 2026. This move is timed precisely with the expiration of patent and data exclusivity protections for Novo Nordisk's (NVO) branded GLP-1 drugs, creating a significant first-mover opportunity in the Canadian generic market. By leveraging its digital platform for 24/7 consultations and personalized care, HIMS aims to disrupt a market where branded treatments currently cost upwards of C$200 per month, targeting a large addressable population. This expansion is a key component of a broader international growth strategy, evidenced by its recent acquisition of European digital health platform ZAVA. While the market's immediate reaction was a modest 0.7% share price increase, the stock has more than doubled in 2025, indicating strong investor confidence in its disruptive strategy, a sentiment underscored by the highly positive signal for HIMS (0.8) and the corresponding negative signal for incumbent Novo Nordisk (-0.5).

Key Decisions for Investors

• For investors in Hims & Hers, this announcement validates the company's international growth thesis and provides a clear, actionable catalyst for revenue expansion beginning in 2026, justifying a review of long-term growth models.
• This development represents a material future headwind for Novo Nordisk in the Canadian market and serves as a key indicator of the competitive landscape for branded GLP-1s as patents begin to expire globally.
• It is prudent to monitor Hims & Hers' execution in navigating Canadian healthcare regulations and its ability to secure a significant cost advantage to effectively capture market share post-launch.